Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Mais filtros

Base de dados
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Br J Dermatol ; 188(1): 52-63, 2023 01 23.
Artigo em Inglês | MEDLINE | ID: mdl-36689500

RESUMO

BACKGROUND: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disorder with significant morbidity. The pathogenesis remains incompletely understood although immune dysregulation plays an important role. It is challenging to treat and approximately 50% of patients respond clinically to adalimumab, the only licensed treatment. OBJECTIVES: To examine differences between lesional and nonlesional HS skin at baseline using bulk RNA sequencing, and to compare the transcriptome in the skin before and after 12 weeks of treatment with adalimumab. To examine transcriptomic differences between adalimumab responders and nonresponders using Hidradenitis Suppurativa Clinical Response and the International Hidradenitis Suppurativa Severity Score System (IHS4); and to compare transcriptomic differences based on disease severity (Hurley stage and IHS4). METHODS: We completed bulk RNA sequencing on lesional and nonlesional skin samples of patients before and after 12 weeks of treatment with adalimumab. RESULTS: Baseline differentially expressed genes and pathways between lesional and nonlesional skin highlighted chemokines and antimicrobial peptides produced by keratinocytes; B-cell function; T-cell-receptor, interleukin-17 and nuclear factor-κB signalling; and T-helper-cell differentiation. Transcriptomic differences were identified in lesional skin at baseline, between subsequent responders and nonresponders. Patients with severe HS who did not respond to adalimumab had enriched complement and B-cell activation pathways at baseline. In addition, logistic regression identified CCL28 in baseline lesional HS skin as a potential biomarker of treatment response. CONCLUSIONS: This highlights the potential for targeting B-cell and complement pathways in HS treatment and the potential of stratifying patients at baseline to the most suitable treatment based on the skin transcriptome. CCL28 has not previously been identified in HS skin and has potential clinical relevance due to its antimicrobial function and homing of B and T cells at epithelial surfaces. Our results provide data to inform future translational and clinical studies on therapeutics in HS.


Assuntos
Hidradenite Supurativa , Humanos , Adalimumab/uso terapêutico , Hidradenite Supurativa/tratamento farmacológico , Transdução de Sinais , Transcriptoma , Índice de Gravidade de Doença
3.
J Invest Dermatol ; 142(2): 459-468.e15, 2022 02.
Artigo em Inglês | MEDLINE | ID: mdl-34364884

RESUMO

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease characterized by the formation of nodules, abscesses, and fistulae at intertriginous sites. The skin-gut axis is an area of emerging research in inflammatory skin disease and is a potential contributory factor to the pathogenesis of HS. A total of 59 patients with HS provided fecal samples and nasal and skin swabs of affected sites for analysis. A total of 30 healthy controls provided fecal samples, and 20 healthy controls provided nasal and skin swabs. We performed bacterial 16S ribosomal RNA gene amplicon sequencing on total DNA derived from the samples. Microbiome alpha diversity was significantly lower in the fecal, skin, and nasal samples of individuals with HS, which may be secondary to disease biology or related to antibiotic usage. Ruminococcus gnavus was more abundant in the fecal microbiome of individuals with HS, which is also reported in Crohn's disease, suggesting comorbidity due to shared gut microbiota alterations. Finegoldia magna was overabundant in HS skin samples relative to that in the healthy controls. It is possible that local inflammation is driven by F. magna by promoting the formation of neutrophil extracellular traps. These alterations in both the gut and skin microbiome in HS warrant further exploration, and therapeutic strategies, including fecal microbiota transplant or bacteriotherapy, could be of benefit.


Assuntos
Microbioma Gastrointestinal/imunologia , Hidradenite Supurativa/microbiologia , Pele/microbiologia , Adulto , Idoso , Estudos de Casos e Controles , Clostridiales/imunologia , Clostridiales/isolamento & purificação , Armadilhas Extracelulares/imunologia , Transplante de Microbiota Fecal , Fezes/microbiologia , Feminino , Firmicutes/imunologia , Firmicutes/isolamento & purificação , Hidradenite Supurativa/imunologia , Hidradenite Supurativa/patologia , Hidradenite Supurativa/terapia , Humanos , Masculino , Pessoa de Meia-Idade , Pele/imunologia , Pele/patologia , Adulto Jovem
4.
J Invest Dermatol ; 137(11): 2389-2395, 2017 11.
Artigo em Inglês | MEDLINE | ID: mdl-28652108

RESUMO

Hidradenitis suppurativa (HS) is a chronic, inflammatory, and debilitating disease of hair follicles with 1-4% prevalence and high morbidity. There is a dearth of information on the pathogenesis and immune dysregulation underlying HS; therefore, we carried out a detailed analysis of skin-infiltrating T cells. Cells isolated from skin biopsy samples and blood from HS patients and healthy control subjects were analyzed by 16-parameter flow cytometry to provide detailed profiles of CD4 T-cell subsets. We observed substantial infiltration of inflammatory T cells with a striking T helper (Th) type 17-skewed cytokine profile in HS skin; these cells expressed the Th17 lineage marker CD161 and IL-17, as well as proinflammatory cytokines GM-CSF, IL-22, IFN-γ, and tumor necrosis factor. Regulatory T cells were also enriched in HS lesional skin; however, the ratio of Th17 to regulatory T cells was nonetheless highly dysregulated in favor of Th17 cells. In contrast, lesional skin from anti-tumor necrosis factor-treated HS patients who showed substantial clinical improvement exhibited a significant reduction in the frequency of Th17 cells and normalization of the Th17 to regulatory T cell ratio. These data suggest that inhibition of pathogenic IL-17 via tumor necrosis factor blockade is associated with improvement in immune dysregulation in HS and may provide a rationale for targeting IL-17 in the disease.


Assuntos
Hidradenite Supurativa/imunologia , Hidradenite Supurativa/patologia , Linfócitos T Reguladores/imunologia , Células Th17/imunologia , Fator de Necrose Tumoral alfa/antagonistas & inibidores , Adulto , Biópsia por Agulha , Estudos de Casos e Controles , Células Cultivadas/efeitos dos fármacos , Estudos de Coortes , Feminino , Hidradenite Supurativa/tratamento farmacológico , Humanos , Imunidade Celular/efeitos dos fármacos , Imunidade Celular/fisiologia , Imuno-Histoquímica , Interleucina-17/imunologia , Interleucina-17/metabolismo , Masculino , Valores de Referência , Linfócitos T Reguladores/efeitos dos fármacos , Linfócitos T Reguladores/metabolismo , Células Th17/metabolismo , Fator de Necrose Tumoral alfa/farmacologia
5.
JAAD Case Rep ; 5(3): 271-273, 2019 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-30891478
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA